Imaging of cancer therapy-induced central nervous system toxicity

Neurologic Clinics

Volumn 32, Issue 1, 2014, Pages 147-157

  Dietrich, Jörg ^a   Klein, Joshua P ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Central nervous system; Chemotherapy; Imaging; Neurotoxicity; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; OXYGEN 15; TAMOXIFEN;

ARTERY THROMBOSIS; BLOOD BRAIN BARRIER; BLOOD FLOW; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN SIZE; BRAIN VENTRICLE DILATATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CANCER THERAPY; CEREBROSPINAL FLUID; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOSIS; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; HYDROCEPHALUS; LEUKOENCEPHALOPATHY; NEUROIMAGING; NEUROTOXICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ATTENUATION; RADIATION NECROSIS; REVIEW; SCINTIGRAPHY; SENSITIVITY ANALYSIS; SHORT TERM MEMORY; SIDE EFFECT; SUSCEPTIBILITY WEIGHTED IMAGING; SYSTEMIC THERAPY; TUMOR GROWTH; TUMOR NECROSIS; TUMOR RECURRENCE; WHITE MATTER; X RAY;

CANCER; CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY; IMAGING; NEUROTOXICITY; RADIATION THERAPY;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; NEUROIMAGING; RADIOTHERAPY;

EID: 84888197351     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2013.07.004     Document Type: Review

References (29)

1. Dietrich J., Monje M., Wefel J., et al. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008, 13:1285-1295.
2. Arrillaga-Romany I., Dietrich J. Imaging findings in cancer therapy-associated neurotoxicity. Semin Neurol 2012, 32:476-486.
3. Dietrich J., Wen P. Neurologic complications of chemotherapy. Cancer neurology in clinical practice 2008, 287-326. Humana Press Inc, Totowa (NJ). D. Schiff, S. Kesari, P. Wen (Eds.).
4. Galloway T.J., Indelicato D.J., Amdur R.J., et al. Second tumors in pediatric patients treated with radiotherapy to the central nervous system. Am J Clin Oncol 2012, 35:279-283.
5. Wang Y.X., King A.D., Zhou H., et al. Evolution of radiation-induced brain injury: MR imaging-based study. Radiology 2010, 254:210-218.
6. Rahmathulla G., Marko N.F., Weil R.J. Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. JClin Neurosci 2013, 20(4):485-502.
7. Yoshii Y. Pathological review of late cerebral radionecrosis. Brain Tumor Pathol 2008, 25:51-58.
8. Bradley W.G. MR appearance of hemorrhage in the brain. Radiology 1993, 189:15-26.
9. Hygino da Cruz L.C., Rodriguez I., Domingues R.C., et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011, 32:1978-1985.
10. Tanaka S., Louis D.N., Curry W.T., et al. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat Rev Clin Oncol 2013, 10:14-26.
11. Hu L.S., Baxter L.C., Smith K.A., et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009, 30:552-558.
12. Chao S.T., Suh J.H., Raja S., et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001, 96:191-197.
13. Deprez S., Amant F., Smeets A., et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. JClin Oncol 2012, 30:274-281.
14. Koppelmans V., Breteler M.M., Boogerd W., et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. JClin Oncol 2012, 30:1080-1086.
15. McDonald B.C., Conroy S.K., Ahles T.A., et al. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. JClin Oncol 2012, 30:2500-2508.
16. McDonald B.C., Conroy S.K., Smith D.J., et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun 2013, 30(Suppl):S117-S125.
17. Inagaki M., Yoshikawa E., Matsuoka Y., et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007, 109:146-156.
18. Koppelmans V., de Ruiter M.B., van der Lijn F., et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat 2012, 132:1099-1106.
19. McDonald B.C., Conroy S.K., Ahles T.A., et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 2010, 123:819-828.
20. Abraham J., Haut M.W., Moran M.T., et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008, 8:88-91.
21. de Ruiter M.B., Reneman L., Boogerd W., et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 2011, 32:1206-1219.
22. Deprez S., Amant F., Yigit R., et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 2011, 32:480-493.
23. Ferguson R.J., McDonald B.C., Saykin A.J., et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. JClin Oncol 2007, 25:3866-3870.
24. Kesler S.R., Bennett F.C., Mahaffey M.L., et al. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res 2009, 15:6665-6673.
25. Kesler S.R., Kent J.S., O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 2011, 68:1447-1453.
26. Silverman D.H., Dy C.J., Castellon S.A., et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007, 103:303-311.
27. Bartynski W.S., Boardman J.F. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007, 28:1320-1327.
28. Marinella M.A., Markert R.J. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J 2009, 39:826-834.
29. Zhao Z., Lan Y., Bai S., et al. Late-onset radiation-induced optic neuropathy after radiotherapy for nasopharyngeal carcinoma. JClin Neurosci 2013, 20(5):702-706.